Facile synthesis of high specific activity 4-[1-14 C]butyl-1,2-diphenylpyrazolidine-3,5-dione (phenylbutazone) using nucleophilic substitution.

Metabolism, environmental fate, and low concentration food residue studies would be facilitated by the use of radiolabeled test articles that can be readily quantified within complex matrices. However, radiochemical approaches for such studies require high specific activities to allow analytical detection of correspondingly low masses of test article. The synthesis of high specific activity (>50 µCi/µmol) [14 C]-radiolabeled phenylbutazone presents a challenge using existing methodology, mainly due to the low solvent volumes required and vigorous refluxing needed to close the pyrazolidinedione ring. Herein, we report on the significant modification of an existing method that allows the synthesis of low masses of high specific activity (>50 µCi/µmol) [14 C]-phenylbutazone under mild conditions with simple purification and high yield. The closure of the pyrazolidinedione ring of 1,2-diphenyl-3,5-pyrazolidinedione was accomplished as a first step with unlabeled 1,2-diphenylhydrazine and diethyl malonate in 32% yield under gram-scale conditions, which avoided the challenges of low solvent use and vigorous refluxing. Low mass of high specific activity n-[1-14 C]-butyl bromide was then added via a nucleophilic substitution reaction as a final step. Yields ranged from 65% to 92% during multiple synthetic attempts with unlabeled butyl bromide and were greatly influenced by reaction stoichiometry and the selection of base.

[Chemical synthesis of phenylbutazone hydroperoxide and testing of the substance for heart action under in vitro and in vivo conditions]. / Chemische Darstellung von Phenylbutazon-hydroperoxid und Prüfung der Substanz auf Herzwirksamkeit unter In-vitro-und In-vivo-Bedingungen.

Phenylbutazone (4-n-butyl-1,2-diphenyl-pyrazolidine-3,5-dione) 1 is an easily autoxidable substance which forms a crystalline and stable hydroperoxide 3. The decomposition of 3 yields products which were investigated as metabolites of the drug. In isolated heart preparations of guinea pigs and rabbit hearts in vivo the hydroperoxide 3 shows a significantly stronger cardiodepressive and coronary constricting effect compared to phenylbutazone 1, 4-hydroxy-phenylbutazone 4 and the open-ring decomposition product of the hydroperoxide 5. The results indicate the significance of the hydroperoxide 3 for the total efficiency of phenylbutazone and explain the side effects of the substance.

Preparation and evaluation of electrophilic derivatives of phenylbutazone as inhibitors of prostaglandin-H synthase.

The chemical syntheses and biological evaluation of several potential irreversible inhibitors for prostaglandin (PGH) synthase are described. These inhibitors were modeled after the nonsteroidal antiinflammatory (NSAI) drug phenylbutazone (4-n-butyl-1,2-diphenyl-3,5-pyrazolidinedione). Electrophilic functionalities such as an alpha-bromoacetamide, an alpha-chloroacetamide, a phenylurethane, a propargyl chloride, and several alpha,beta-unsaturated Michael acceptors were incorporated at the 4-position of the pyrazolidinedione ring structure. None of the derivatives showed evidence of irreversible inhibition of PGH synthase, although several were nearly as potent inhibitors of this enzyme as phenylbutazone. The nitrile obtained from 1,4-conjugate addition of cyanide to one of the unsaturated derivatives was considerably more potent as an inhibitor of PGH synthase than was phenylbutazone.

Prostaglandin-H synthase inhibition by malonamides. Ring-opened analogues of phenylbutazone.

Recent reports of serious concern regarding the safe clinical use of phenylbutazone and its hydroxylated metabolite (oxyphenbutazone) as antiinflammatory agents have prompted the further investigation of ring-opened (malonamide) derivatives as potentially preferable therapeutic derivatives. Earlier reports have claimed reduced toxicity among similar derivatives. These studies reveal the relative degree of prostaglandin-H (PGH) synthase inhibitory activity among a series of malonamide derivatives. Contrary to observations in the pyrazolidinedione series, incorporation of a nonpolar butyl side chain in these malonamides was not beneficial but, rather, detrimental to enzyme-inhibitory activity. Although none of the reported nonbutylated malonamides was as potent an inhibitor of this enzyme as phenylbutazone, they all showed some inhibitory activity. PGH synthase inhibitory activity was especially pronounced in the bis(p-hydroxy anilide) derivatives, even extending to succinamide and adipamide derivatives. Of some interest is the observation that all of these p-hydroxy anilide derivatives were more potent inhibitors of this enzyme than acetaminophen.

Diagnostic reagents in drug allergy: immunochemical specificity in the 1,2-diphenyl-pyrazolidinedione series.

Chemically defined haptenic reagents and haptenic conjugates were synthesized to be used for skin tests in allergic patients and for serological tests. One series of reagents is based on an open-chain derivative which is formed by reaction of the oxidation product of phenylbutazone, 4-hydroxyphenylbutazone, with amino functions. A second series uses the intact 1,2-diphenyl-pyrazolidine-3,5-dione molecule which is substituted in the 4-position with acetic acid. Both haptens are used in conjunction with spacer molecules which provide considerable distances between haptenic moiety and carriers. The skin test reagents are hexavalent conjugates based on the bis-penta-L-lysine carrier "PAL". Rabbit and guinea-pig antisera against the haptens were obtained by immunizations with human serum albumin conjugates. Data obtained from passive cutaneous anaphylaxis and from ELISA tests show that there is generally only slight cross-reactivity between the two series of haptenic reagents. Also, there is only modest cross-reactivity between intact drugs and haptenic reagents. No measurable crossreactions were noted between 1-phenyl-2,3-dimethyl-3-pyrazolin-5-one derivatives and haptenic reagents of the 1,2-diphenyl-pyrazolidinedione series.